Mylan N V Receivables Turnover Ratio (MYL), from the third quarter 2020 to the third quarter 2019 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Mylan N v   (NASDAQ: MYL)
 

Mylan N V Accounts Receivables Turnover Ratio from the third quarter 2020 to the third quarter 2019

Quarterly Results, Trends, Rankings, Statistics


Accounts Receivable turnover ratio remained unchanged during the third quarter 2020, compared to the previous quarter at 3.99 pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Average collection period, for Mylan N V 's accounts receivable remained unchanged at 91 days, in the Sep 30 2020 quarter.

If we take a look into Healthcare sector 466 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3270, from overall ranking in the second quarter 2020 at 3312.

What is Receivable Turnover Ratio?
What is Mylan N V Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYL Receivables Turnover Ratio (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter
Y / Y Receivable Change 0.55 % 1.83 % -0.14 % 6.17 % -0.02 %
Y / Y Revenue Change 0.35 % -4.22 % 4.96 % 3.67 % 3.47 %
Receivable Turnover Ratio (TTM) 3.99 3.99 4.05 4 4.03
MYL's Total Ranking # 3270 # 3312 # 3332 # 3713 # 3467
Accounts Receivable average collection period days 92 91 90 91 91
Seq. Receivable Change 7.66 % -0.77 % -9.29 % 3.76 % 9.03 %
Seq. Revenue Change 8.82 % 4.28 % -17.94 % 7.77 % 3.86 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 467
Overall Market # 3270

Receivable Turnover Ratio Statistics
High Average Low
5.57 4.28 3.5
(Sep. 30, 2006)   (Sep 30 2015)





MYL Company Profile • Back to MYL Efficiency Comparisons • Compare MYL Receivables Turnover Ratio to its Competitors

Financial Statements
Mylan N V 's Accounts Receivable $ 2,964 Millions Visit MYL's Balance sheet
Mylan N V 's Sales TTM $ 11,514 Millions Visit MYL's Income Statement
Sources of MYL's Revenues Visit MYL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MYL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MYL's Growth Rates MYL's Roa MYL's Inventory Turnover Ratio MYL's Dividend Comparisons
MYL's Profitability Ratios MYL's Roi MYL's Asset Turnover Ratio MYL's Dividend Growth
MYL's Valuation Ratios MYL's Roe MYL's Financial Strength Ratios MYL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2020, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2020 Receivable at quarter ending Sep 30 2020
Insulet Corporation  10.64 $ 867.694  Millions$ 81.575  Millions
Clearpoint Neuro Inc   10.52 $ 12.323  Millions$ 1.172  Millions
Allied Healthcare Products inc   10.48 $ 34.108  Millions$ 3.255  Millions
Bicycle Therapeutics Plc  10.46 $ 11.823  Millions$ 1.130  Millions
Strongbridge Biopharma plc  10.45 $ 28.111  Millions$ 2.690  Millions
Regeneron Pharmaceuticals Inc   10.27 $ 8,243.700  Millions$ 802.400  Millions
Acorda Therapeutics Inc   10.14 $ 165.303  Millions$ 16.303  Millions
Zai Lab Limited  10.12 $ 46.849  Millions$ 4.631  Millions
Lifeloc Technologies Inc   10.11 $ 6.981  Millions$ 0.690  Millions
Insmed Inc  10.11 $ 168.706  Millions$ 16.689  Millions
Immucell Corporation  10.09 $ 15.231  Millions$ 1.510  Millions
Sanara Medtech Inc   10.03 $ 14.151  Millions$ 1.411  Millions
Global Blood Therapeutics Inc.  10.01 $ 84.616  Millions$ 8.454  Millions
Lensar Inc   9.92 $ 7.145  Millions$ 0.720  Millions
Agenus Inc  9.89 $ 91.407  Millions$ 9.245  Millions
Irhythm Holdings Inc   9.84 $ 245.691  Millions$ 24.978  Millions
Viemed Healthcare Inc   9.82 $ 121.555  Millions$ 12.374  Millions
Utah Medical Products Inc  9.76 $ 42.000  Millions$ 4.305  Millions
Imac Holdings Inc   9.72 $ 13.616  Millions$ 1.401  Millions
La Jolla Pharmaceutical Company  9.68 $ 29.718  Millions$ 3.071  Millions
Karyopharm Therapeutics Inc   9.64 $ 91.081  Millions$ 9.447  Millions
Pacira Biosciences inc   9.53 $ 421.097  Millions$ 44.169  Millions
Acadia Pharmaceuticals Inc   9.51 $ 419.074  Millions$ 44.089  Millions
Zynex inc   9.42 $ 68.679  Millions$ 7.288  Millions
Sunlink Health Systems Inc   9.40 $ 46.583  Millions$ 4.954  Millions
Inogen Inc   9.30 $ 313.426  Millions$ 33.709  Millions
Abiomed Inc   9.21 $ 802.857  Millions$ 87.159  Millions
Rigel Pharmaceuticals Inc  9.15 $ 105.571  Millions$ 11.532  Millions
Enzo Biochem Inc  9.15 $ 84.469  Millions$ 9.230  Millions
Seres Therapeutics Inc   9.13 $ 23.273  Millions$ 2.548  Millions

Date modified: 2026-09-08T15:10:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.